Status:
COMPLETED
Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United Kingdom
Lead Sponsor:
AstraZeneca
Conditions:
Non-Small Cell Lung Cancer NSCLC
Eligibility:
All Genders
18+ years
Brief Summary
This is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with locally advanced, unresectable Stage III non-small cell lung canc...
Detailed Description
Primary Objectives The primary study objectives, in patients with locally advanced, unresectable Stage III NSCLC treated with durvalumab as part of the UK EAP or non-EAP, are: 1. To describe clinica...
Eligibility Criteria
Inclusion
- Patient has documented diagnosis of locally advanced, unresectable Stage III NSCLC
- Patient has received platinum-based CRT and received ≥1 dose of durvalumab
- Patient was initiated on durvalumab (index event) between 1st September 2017 and 31st December 2019 via the EAP or non-EAP
- Patient was aged ≥18 years at durvalumab initiation
Exclusion
- Patients who participated in the PACIFIC-R study
- Participation in any clinical study with an investigational product at the time of durvalumab initiation or during the observational period
Key Trial Info
Start Date :
June 24 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 28 2022
Estimated Enrollment :
115 Patients enrolled
Trial Details
Trial ID
NCT04667312
Start Date
June 24 2021
End Date
September 28 2022
Last Update
October 2 2023
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
East Kent Hospital
Canterbury, United Kingdom, CT1 3NG
2
Velindre Hospital
Cardiff, United Kingdom, CF14 2TL
3
Harrogate and district NHS foundation Trust
Harrogate, United Kingdom, HG2 7SX
4
Leeds Teaching Hospitals NHS Trust
Leeds, United Kingdom, LS9 7TF